Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1755-3768.2009.01560.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progressive anterior segment involvement of an infant with corneoscleral juvenile xanthogranuloma refractory to topical steroids.
Am J Ophthalmol Case Rep
December 2024
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Purpose: To report a case of corneoscleral juvenile xanthogranuloma (JXG) with progressive anterior segment involvement refractory to topical steroids.
Observations: A 4-month-old male was referred for a new-onset subconjunctival lesion in the right eye. He was found to have a thickened, yellow corneoscleral lesion and hyphema, presumed to be ocular JXG.
[Methotrexate therapy for primary intraocular lymphoma: a case report].
Zhonghua Yan Ke Za Zhi
January 2025
Department of Ophthalmology, Qingyuan Hospital Affiliated to Guangzhou Medical University (Qingyuan People's Hospital), Qingyuan511518, China.
Article Synopsis
- A 63-year-old man experienced vision loss in his left eye and blurred vision in his right eye for four months, initially diagnosed as uveitis by an ophthalmology department.
- After further evaluation, he was found to have central nervous system lymphoma, leading to systemic treatment, but his vision continued to deteriorate.
- Eventually, tests revealed intraocular lymphoma in both eyes, and he received eight intravitreal methotrexate injections, resulting in significant improvement in his visual acuity.
Bilateral primary vitreoretinal lymphoma masquerading as fungal endophthalmitis- a case report.
J Ophthalmic Inflamm Infect
December 2024
Shroff Eye Center, Kailash Colony, New Delhi, India.
Purpose: To report a case of bilateral primary vitreoretinal lymphoma (PVRL) masquerading as endophthalmitis in a patient with a history of bilateral cataract surgery and COVID-19.
Observation: A 60-year-old male patient presented with diminution of vision in both the eyes. There was a history of bilateral cataract surgery done 2 months back at a gap of one week and COVID-19 infection treated with high dose systemic corticosteroids.
Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review.
Eye (Lond)
December 2024
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Proliferative Vitreoretinopathy (PVR) is a major complication of surgical repair for Rhegmatogenous Retinal Detachment (RRD). Methotrexate (MTX), a folate antimetabolite, has shown promise in targeting the pathological processes involved in PVR, such as cell proliferation inhibition, fibrosis and anti-inflammation. Systematic review examines the use of MTX in PVR by analysing different administration methods and outcomes.
View Article and Find Full Text PDFIntraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment.
Am J Ophthalmol Case Rep
December 2024
Department of Ophthalmology at University of Cincinnati, 231 Albert Sabin Way, 5th Floor, Cincinnati, OH, 45267-0527, USA.
Purpose: To present a case of aggressive proliferative vitreoretinopathy (PVR) managed with intraoperative and postoperative intravitreal methotrexate (MTX) in a patient with congenital aniridia (CI).
Observations: A 41-year-old female with a history of CI, living-related conjunctival-kerato-limbal allograft transplantation, and multiple intraocular surgeries presents with tractional retinal detachment (TRD) and aggressive grade C PVR 52 days after a primary 23-gauge pars plana vitrectomy (PPV) with rhegmatogenous retinal detachment repair. She underwent 23-gauge PPV, TRD repair including membrane peeling of pre- and sub-retinal PVR, 5000 centistoke silicone oil exchange, endolaser, and MTX infusion.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!